Das lokalisierte Prostatakarzinom

V. W. Sailer; S. Perner; P. Wild; J. Köllermann

doi:10.1007/s00292-021-00997-8

Das lokalisierte Prostatakarzinom

Translated title of the contribution: Localized prostate cancer

V. W. Sailer^*, S. Perner, P. Wild, J. Köllermann

^*Corresponding author for this work

Institute of Pathology

Abstract

Prostate cancer is the most prevalent noncutaneous cancer in men. The Gleason grading is considered to be the strongest prognostic parameter regarding progression-free survival and overall survival. The original grading system has been modified during the last decade resulting in a more precise prognostic tool. The pretreatment Gleason score guides clinical management and is a key component in S3 guidelines for prostate cancer. In addition to Gleason score several other histologic findings in prostate needle biopsy influence patient management. In this second part of our CME series about prostate cancer, we will discuss the diagnosis of prostate cancer and current guidelines for reporting prostate cancer. In addition, we will highlight prostate lesions of urothelial origin and neuroendocrine prostate cancer as well as prognostic biomarkers.

Translated title of the contribution	Localized prostate cancer
Original language	German
Journal	Pathologe
Volume	42
Issue number	6
Pages (from-to)	603-616
Number of pages	14
ISSN	0172-8113
DOIs	https://doi.org/10.1007/s00292-021-00997-8
Publication status	Published - 11.2021

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)
Centers: University Cancer Center Schleswig-Holstein (UCCSH)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00292-021-00997-8

Cite this

@article{03752467ab044b9999edc6eb7de4a2c6,

title = "Das lokalisierte Prostatakarzinom",

abstract = "Prostate cancer is the most prevalent noncutaneous cancer in men. The Gleason grading is considered to be the strongest prognostic parameter regarding progression-free survival and overall survival. The original grading system has been modified during the last decade resulting in a more precise prognostic tool. The pretreatment Gleason score guides clinical management and is a key component in S3 guidelines for prostate cancer. In addition to Gleason score several other histologic findings in prostate needle biopsy influence patient management. In this second part of our CME series about prostate cancer, we will discuss the diagnosis of prostate cancer and current guidelines for reporting prostate cancer. In addition, we will highlight prostate lesions of urothelial origin and neuroendocrine prostate cancer as well as prognostic biomarkers.",

author = "Sailer, {V. W.} and S. Perner and P. Wild and J. K{\"o}llermann",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2021",

month = nov,

doi = "10.1007/s00292-021-00997-8",

language = "Deutsch",

volume = "42",

pages = "603--616",

journal = "Der Pathologe",

issn = "1432-1963",

number = "6",

}

TY - JOUR

T1 - Das lokalisierte Prostatakarzinom

AU - Sailer, V. W.

AU - Perner, S.

AU - Wild, P.

AU - Köllermann, J.

PY - 2021/11

Y1 - 2021/11

N2 - Prostate cancer is the most prevalent noncutaneous cancer in men. The Gleason grading is considered to be the strongest prognostic parameter regarding progression-free survival and overall survival. The original grading system has been modified during the last decade resulting in a more precise prognostic tool. The pretreatment Gleason score guides clinical management and is a key component in S3 guidelines for prostate cancer. In addition to Gleason score several other histologic findings in prostate needle biopsy influence patient management. In this second part of our CME series about prostate cancer, we will discuss the diagnosis of prostate cancer and current guidelines for reporting prostate cancer. In addition, we will highlight prostate lesions of urothelial origin and neuroendocrine prostate cancer as well as prognostic biomarkers.

AB - Prostate cancer is the most prevalent noncutaneous cancer in men. The Gleason grading is considered to be the strongest prognostic parameter regarding progression-free survival and overall survival. The original grading system has been modified during the last decade resulting in a more precise prognostic tool. The pretreatment Gleason score guides clinical management and is a key component in S3 guidelines for prostate cancer. In addition to Gleason score several other histologic findings in prostate needle biopsy influence patient management. In this second part of our CME series about prostate cancer, we will discuss the diagnosis of prostate cancer and current guidelines for reporting prostate cancer. In addition, we will highlight prostate lesions of urothelial origin and neuroendocrine prostate cancer as well as prognostic biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85117031778&partnerID=8YFLogxK

U2 - 10.1007/s00292-021-00997-8

DO - 10.1007/s00292-021-00997-8

M3 - Zeitschriftenaufsätze

AN - SCOPUS:85117031778

VL - 42

SP - 603

EP - 616

JO - Der Pathologe

JF - Der Pathologe

SN - 1432-1963

IS - 6

ER -

Das lokalisierte Prostatakarzinom

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this